ReviewPharmaceuticals (Basel, Switzerland)2023
The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome-Plant Metabolites in IBS Treatment.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Trial
- ATP-P2X3 Signaling as a Shared Neural Sensitization Pathway in Endometriosis and Irritable Bowel Syndrome: Mechanisms and Therapeutic Implications.Biomedicines · 2026Review
- Natural variation in antimicrobial activity and composition of the secreted metabolomes of the model moss Ceratodon purpureus.Scientific reports · 2026Article
- Physical and Mental Health as Biopsychosocial Correlates and Pathways Associated With Symptom Severity in Irritable Bowel Syndrome: A Cross-Sectional Structural Equation Modeling Study.Neurogastroenterology and motility · 2026Article
- G Protein-Coupled Receptors in Irritable Bowel Syndrome: Mechanisms and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Metformin-Associated Gastrointestinal Intolerance: A Narrative Review of Mechanisms and Clinical Management.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- Pathophysiological Mechanisms and Nonpharmacological Interventions in Irritable Bowel Syndrome: Current Insights and Future Directions.Journal of nutrition and metabolism · 2026Review
- Efficacy and mechanisms of vagus nerve stimulation in irritable bowel syndrome: a comprehensive literature review.Frontiers in immunology · 2026Review
- Patient-centered gastrointestinal function assessment technologies: a paradigm shift from traditional approaches to non-invasive innovations.Frontiers in physiology · 2026Review
- Efficacy and safety of non-invasive transcutaneous nerve stimulation in patients with irritable bowel syndrome: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Article
- Could the Therapeutic Effect of Physical Activity on Irritable Bowel Syndrome Be Mediated Through Changes to the Gut Microbiome? A Narrative and Hypothesis Generating Review.Neurogastroenterology and motility · 2025Review
- Effects of a low-FODMAP diet on patients with endometriosis, a prospective cohort study.BMC women's health · 2025Article
- Should We Treat SIBO Patients? Impact on Quality of Life and Response to Comprehensive Treatment: A Real-World Clinical Practice Study.Nutrients · 2025Article
- Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.Nutrients · 2024Review
- Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome.International journal of molecular sciences · 2024Review
- The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome.Journal of clinical medicine · 2024Review
- miRNA-let7b5p alleviates visceral hypersensitivity by inhibiting the activation of spinal microglial in male IBS-like rats.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The visceral stimuli from the digestive tract are transmitted via afferent nerves through the spinal cord to the brain, where they are felt as pain. The overreaction observed in the brain of irritable bowel syndrome (IBS) patients may be due to increased peripheral sensitivity to stimuli from the gastrointestinal tract. Although the exact pathway is uncertain, attenuation of visceral hypersensitivity is still of interest in treating IBS. It has been shown that stress stimulates the sympathetic nervous system while inhibiting the vagus nerve (VN). In addition, stress factors lead to dysbiosis and chronic low-grade inflammation of the intestinal mucosa, which can lead to lower gastrointestinal visceral hypersensitivity. Therefore, an important goal in the treatment of IBS is the normalization of the intestinal microflora. An interesting option seems to be nutraceuticals, including Terminalia chebula, which has antibacterial and antimicrobial activity against various pathogenic Gram-positive and Gram-negative bacteria. Additionally, short-term transcutaneous vagus nerve stimulation can reduce the stress-induced increase in intestinal permeability, thereby reducing inflammation. The conducted studies also indicate a relationship between the stimulation of the vagus nerve (VN) and the activation of neuromodulatory networks in the central nervous system. Therefore, it seems reasonable to conclude that a two-way action through stimulating the VN and using nutraceuticals may become an effective therapy in treating IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.